000141332912/312021Q2FALSE800014133292021-01-012021-06-300001413329us-gaap:CommonStockMember2021-01-012021-06-300001413329pm:A2.900Notesdue2021Member2021-01-012021-06-300001413329pm:A2.625Notesdue2022Member2021-01-012021-06-300001413329pm:A2.375Notesdue2022Member2021-01-012021-06-300001413329pm:A2.500Notesdue20221Member2021-01-012021-06-300001413329pm:A2.500Notesdue20222Member2021-01-012021-06-300001413329pm:A2.625Notesdue2023Member2021-01-012021-06-300001413329pm:A2.125Notesdue2023Member2021-01-012021-06-300001413329pm:A3.600Notesdue2023Member2021-01-012021-06-300001413329pm:A2.875Notesdue20241Member2021-01-012021-06-300001413329pm:A2.875Notesdue20242Member2021-01-012021-06-300001413329pm:A0.625Notesdue2024Member2021-01-012021-06-300001413329pm:A3.250Notesdue2024Member2021-01-012021-06-300001413329pm:A2.750Notesdue2025Member2021-01-012021-06-300001413329pm:A3.375Notesdue2025Member2021-01-012021-06-300001413329pm:A2.750Notesdue2026Member2021-01-012021-06-300001413329pm:A2.875Notesdue2026Member2021-01-012021-06-300001413329pm:A0.125Notesdue2026Member2021-01-012021-06-300001413329pm:A3.125Notesdue2027Member2021-01-012021-06-300001413329pm:A3.125Notesdue2028Member2021-01-012021-06-300001413329pm:A2.875Notesdue2029Member2021-01-012021-06-300001413329pm:A3.375Notesdue2029Member2021-01-012021-06-300001413329pm:A0.800Notesdue2031Member2021-01-012021-06-300001413329pm:A3.125Notesdue2033Member2021-01-012021-06-300001413329pm:A2.000Notesdue2036Member2021-01-012021-06-300001413329pm:A1.875Notesdue2037Member2021-01-012021-06-300001413329pm:A6.375Notesdue2038Member2021-01-012021-06-300001413329pm:A1.450Notesdue2039Member2021-01-012021-06-300001413329pm:A4.375Notesdue2041Member2021-01-012021-06-300001413329pm:A4.500Notesdue2042Member2021-01-012021-06-300001413329pm:A3.875Notesdue2042Member2021-01-012021-06-300001413329pm:A4.125Notesdue2043Member2021-01-012021-06-300001413329pm:A4.875Notesdue2043Member2021-01-012021-06-300001413329pm:A4.250Notesdue2044Member2021-01-012021-06-30xbrli:shares00014133292021-07-22iso4217:USD00014133292020-01-012020-06-30iso4217:USDxbrli:shares00014133292021-04-012021-06-3000014133292020-04-012020-06-3000014133292021-06-3000014133292020-12-3100014133292019-12-3100014133292020-06-300001413329us-gaap:CommonStockMember2019-12-310001413329us-gaap:AdditionalPaidInCapitalMember2019-12-310001413329us-gaap:RetainedEarningsMember2019-12-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001413329us-gaap:TreasuryStockMember2019-12-310001413329us-gaap:NoncontrollingInterestMember2019-12-310001413329us-gaap:RetainedEarningsMember2020-01-012020-06-300001413329us-gaap:NoncontrollingInterestMember2020-01-012020-06-300001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001413329us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001413329us-gaap:TreasuryStockMember2020-01-012020-06-300001413329us-gaap:CommonStockMember2020-06-300001413329us-gaap:AdditionalPaidInCapitalMember2020-06-300001413329us-gaap:RetainedEarningsMember2020-06-300001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001413329us-gaap:TreasuryStockMember2020-06-300001413329us-gaap:NoncontrollingInterestMember2020-06-300001413329us-gaap:CommonStockMember2020-12-310001413329us-gaap:AdditionalPaidInCapitalMember2020-12-310001413329us-gaap:RetainedEarningsMember2020-12-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001413329us-gaap:TreasuryStockMember2020-12-310001413329us-gaap:NoncontrollingInterestMember2020-12-310001413329us-gaap:RetainedEarningsMember2021-01-012021-06-300001413329us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001413329us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001413329us-gaap:TreasuryStockMember2021-01-012021-06-300001413329us-gaap:CommonStockMember2021-06-300001413329us-gaap:AdditionalPaidInCapitalMember2021-06-300001413329us-gaap:RetainedEarningsMember2021-06-300001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001413329us-gaap:TreasuryStockMember2021-06-300001413329us-gaap:NoncontrollingInterestMember2021-06-300001413329us-gaap:CommonStockMember2020-03-310001413329us-gaap:AdditionalPaidInCapitalMember2020-03-310001413329us-gaap:RetainedEarningsMember2020-03-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001413329us-gaap:TreasuryStockMember2020-03-310001413329us-gaap:NoncontrollingInterestMember2020-03-3100014133292020-03-310001413329us-gaap:RetainedEarningsMember2020-04-012020-06-300001413329us-gaap:NoncontrollingInterestMember2020-04-012020-06-300001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001413329us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001413329us-gaap:TreasuryStockMember2020-04-012020-06-300001413329us-gaap:CommonStockMember2021-03-310001413329us-gaap:AdditionalPaidInCapitalMember2021-03-310001413329us-gaap:RetainedEarningsMember2021-03-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001413329us-gaap:TreasuryStockMember2021-03-310001413329us-gaap:NoncontrollingInterestMember2021-03-3100014133292021-03-310001413329us-gaap:RetainedEarningsMember2021-04-012021-06-300001413329us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001413329us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001413329us-gaap:TreasuryStockMember2021-04-012021-06-300001413329pm:A2017PerformanceIncentivePlanMember2017-05-310001413329pm:A2017PerformanceIncentivePlanMember2021-06-30xbrli:pure0001413329pm:A2017NonEmployeeDirectorsPlanMember2017-05-310001413329pm:A2017NonEmployeeDirectorsPlanMember2021-06-300001413329us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001413329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300001413329us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001413329us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-06-300001413329us-gaap:RestrictedStockUnitsRSUMember2021-06-30pm:year0001413329pm:GrantDateFairValueMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001413329pm:FairValueMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001413329us-gaap:PerformanceSharesMember2021-01-012021-06-300001413329us-gaap:PerformanceSharesMember2021-06-30pm:performanceMetric0001413329srt:MinimumMemberus-gaap:PerformanceSharesMember2021-01-012021-06-300001413329srt:MaximumMemberus-gaap:PerformanceSharesMember2021-01-012021-06-300001413329pm:PerformanceShareUnitsOtherPerformanceFactorsMember2021-01-012021-06-300001413329pm:PerformanceShareUnitsTSRRelativeToCustomerPeerGroupMember2021-01-012021-06-300001413329us-gaap:PerformanceSharesMember2020-01-012020-06-300001413329pm:PerformanceShareUnitsOtherPerformanceFactorsMember2020-01-012020-06-300001413329pm:PerformanceShareUnitsTSRRelativeToCustomerPeerGroupMember2020-01-012020-06-300001413329us-gaap:PerformanceSharesMember2021-04-012021-06-300001413329us-gaap:PerformanceSharesMember2020-04-012020-06-300001413329us-gaap:PerformanceSharesMemberpm:GrantDateFairValueMember2021-01-012021-06-300001413329us-gaap:PerformanceSharesMemberpm:FairValueMember2021-01-012021-06-300001413329us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-06-300001413329us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-06-300001413329us-gaap:PensionPlansDefinedBenefitMember2021-04-012021-06-300001413329us-gaap:PensionPlansDefinedBenefitMember2020-04-012020-06-300001413329pm:PostemploymentBenefitPlansMember2021-01-012021-06-300001413329pm:PostemploymentBenefitPlansMember2020-01-012020-06-300001413329pm:PostemploymentBenefitPlansMember2021-04-012021-06-300001413329pm:PostemploymentBenefitPlansMember2020-04-012020-06-300001413329us-gaap:PostretirementBenefitCostsMember2021-01-012021-06-300001413329us-gaap:PostretirementBenefitCostsMember2020-01-012020-06-300001413329us-gaap:PostretirementBenefitCostsMember2021-04-012021-06-300001413329us-gaap:PostretirementBenefitCostsMember2020-04-012020-06-300001413329pm:EuropeanUnionSegmentMember2020-12-310001413329pm:EasternEuropeSegmentMember2020-12-310001413329pm:MiddleEastAfricaSegmentMember2020-12-310001413329pm:SouthSoutheastAsiaSegmentMember2020-12-310001413329pm:EastAsiaAustraliaSegmentMember2020-12-310001413329pm:LatinAmericaCanadaSegmentMember2020-12-310001413329pm:EuropeanUnionSegmentMember2021-01-012021-06-300001413329pm:EasternEuropeSegmentMember2021-01-012021-06-300001413329pm:MiddleEastAfricaSegmentMember2021-01-012021-06-300001413329pm:SouthSoutheastAsiaSegmentMember2021-01-012021-06-300001413329pm:EastAsiaAustraliaSegmentMember2021-01-012021-06-300001413329pm:LatinAmericaCanadaSegmentMember2021-01-012021-06-300001413329pm:EuropeanUnionSegmentMember2021-06-300001413329pm:EasternEuropeSegmentMember2021-06-300001413329pm:MiddleEastAfricaSegmentMember2021-06-300001413329pm:SouthSoutheastAsiaSegmentMember2021-06-300001413329pm:EastAsiaAustraliaSegmentMember2021-06-300001413329pm:LatinAmericaCanadaSegmentMember2021-06-300001413329us-gaap:TrademarksMember2021-01-012021-06-300001413329us-gaap:TrademarksMember2021-06-300001413329us-gaap:TrademarksMember2020-12-310001413329us-gaap:DistributionRightsMember2021-01-012021-06-300001413329us-gaap:DistributionRightsMember2021-06-300001413329us-gaap:DistributionRightsMember2020-12-310001413329pm:OtherIncludingFarmerContractsAndIntellectualPropertyRightsMember2021-01-012021-06-300001413329pm:OtherIncludingFarmerContractsAndIntellectualPropertyRightsMember2021-06-300001413329pm:OtherIncludingFarmerContractsAndIntellectualPropertyRightsMember2020-12-310001413329pm:AGSnusAktieselskabMemberus-gaap:TrademarksMember2021-01-012021-06-300001413329pm:TrademarksandDistributionNetworksMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-06-300001413329us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-06-300001413329us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberpm:OtherAccruedLiabilitiesMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberpm:OtherAccruedLiabilitiesMember2020-12-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2020-12-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherLiabilitiesMember2020-12-310001413329us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-06-300001413329us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-12-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberpm:OtherAccruedLiabilitiesMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberpm:OtherAccruedLiabilitiesMember2020-12-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherAssetsMember2020-12-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherLiabilitiesMember2021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherLiabilitiesMember2020-12-310001413329us-gaap:ForeignExchangeContractMember2020-12-310001413329us-gaap:ForeignExchangeContractMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberpm:MarketingAdministrationAndResearchCostsMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberpm:MarketingAdministrationAndResearchCostsMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-01-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-01-012020-06-300001413329us-gaap:ForeignExchangeContractMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:InterestExpenseMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberpm:MarketingAdministrationAndResearchCostsMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberpm:MarketingAdministrationAndResearchCostsMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-04-012021-06-300001413329us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-04-012020-06-300001413329us-gaap:ForeignExchangeContractMembersrt:MaximumMember2021-01-012021-06-300001413329us-gaap:NetInvestmentHedgingMemberpm:ForeignDebtMember2021-01-012021-06-300001413329us-gaap:NetInvestmentHedgingMemberpm:ForeignDebtMember2020-01-012020-06-300001413329us-gaap:NetInvestmentHedgingMemberpm:ForeignDebtMember2021-04-012021-06-300001413329us-gaap:NetInvestmentHedgingMemberpm:ForeignDebtMember2020-04-012020-06-300001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-12-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-03-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-03-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-06-300001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-01-012020-06-300001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-04-012021-06-300001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-04-012020-06-300001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-06-300001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-06-30pm:segment0001413329pm:EuropeanUnionSegmentMember2020-01-012020-06-300001413329pm:EuropeanUnionSegmentMember2021-04-012021-06-300001413329pm:EuropeanUnionSegmentMember2020-04-012020-06-300001413329pm:EasternEuropeSegmentMember2020-01-012020-06-300001413329pm:EasternEuropeSegmentMember2021-04-012021-06-300001413329pm:EasternEuropeSegmentMember2020-04-012020-06-300001413329pm:MiddleEastAfricaSegmentMember2020-01-012020-06-300001413329pm:MiddleEastAfricaSegmentMember2021-04-012021-06-300001413329pm:MiddleEastAfricaSegmentMember2020-04-012020-06-300001413329pm:SouthSoutheastAsiaSegmentMember2020-01-012020-06-300001413329pm:SouthSoutheastAsiaSegmentMember2021-04-012021-06-300001413329pm:SouthSoutheastAsiaSegmentMember2020-04-012020-06-300001413329pm:EastAsiaAustraliaSegmentMember2020-01-012020-06-300001413329pm:EastAsiaAustraliaSegmentMember2021-04-012021-06-300001413329pm:EastAsiaAustraliaSegmentMember2020-04-012020-06-300001413329pm:LatinAmericaCanadaSegmentMember2020-01-012020-06-300001413329pm:LatinAmericaCanadaSegmentMember2021-04-012021-06-300001413329pm:LatinAmericaCanadaSegmentMember2020-04-012020-06-300001413329pm:EuropeanUnionSegmentMemberpm:CombustibleProductsMember2021-01-012021-06-300001413329pm:EuropeanUnionSegmentMemberpm:CombustibleProductsMember2020-01-012020-06-300001413329pm:EuropeanUnionSegmentMemberpm:CombustibleProductsMember2021-04-012021-06-300001413329pm:EuropeanUnionSegmentMemberpm:CombustibleProductsMember2020-04-012020-06-300001413329pm:EasternEuropeSegmentMemberpm:CombustibleProductsMember2021-01-012021-06-300001413329pm:EasternEuropeSegmentMemberpm:CombustibleProductsMember2020-01-012020-06-300001413329pm:EasternEuropeSegmentMemberpm:CombustibleProductsMember2021-04-012021-06-300001413329pm:EasternEuropeSegmentMemberpm:CombustibleProductsMember2020-04-012020-06-300001413329pm:CombustibleProductsMemberpm:MiddleEastAfricaSegmentMember2021-01-012021-06-300001413329pm:CombustibleProductsMemberpm:MiddleEastAfricaSegmentMember2020-01-012020-06-300001413329pm:CombustibleProductsMemberpm:MiddleEastAfricaSegmentMember2021-04-012021-06-300001413329pm:CombustibleProductsMemberpm:MiddleEastAfricaSegmentMember2020-04-012020-06-300001413329pm:SouthSoutheastAsiaSegmentMemberpm:CombustibleProductsMember2021-01-012021-06-300001413329pm:SouthSoutheastAsiaSegmentMemberpm:CombustibleProductsMember2020-01-012020-06-300001413329pm:SouthSoutheastAsiaSegmentMemberpm:CombustibleProductsMember2021-04-012021-06-300001413329pm:SouthSoutheastAsiaSegmentMemberpm:CombustibleProductsMember2020-04-012020-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:CombustibleProductsMember2021-01-012021-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:CombustibleProductsMember2020-01-012020-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:CombustibleProductsMember2021-04-012021-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:CombustibleProductsMember2020-04-012020-06-300001413329pm:CombustibleProductsMemberpm:LatinAmericaCanadaSegmentMember2021-01-012021-06-300001413329pm:CombustibleProductsMemberpm:LatinAmericaCanadaSegmentMember2020-01-012020-06-300001413329pm:CombustibleProductsMemberpm:LatinAmericaCanadaSegmentMember2021-04-012021-06-300001413329pm:CombustibleProductsMemberpm:LatinAmericaCanadaSegmentMember2020-04-012020-06-300001413329pm:CombustibleProductsMember2021-01-012021-06-300001413329pm:CombustibleProductsMember2020-01-012020-06-300001413329pm:CombustibleProductsMember2021-04-012021-06-300001413329pm:CombustibleProductsMember2020-04-012020-06-300001413329pm:EuropeanUnionSegmentMemberpm:ReducedRiskProductsMember2021-01-012021-06-300001413329pm:EuropeanUnionSegmentMemberpm:ReducedRiskProductsMember2020-01-012020-06-300001413329pm:EuropeanUnionSegmentMemberpm:ReducedRiskProductsMember2021-04-012021-06-300001413329pm:EuropeanUnionSegmentMemberpm:ReducedRiskProductsMember2020-04-012020-06-300001413329pm:EasternEuropeSegmentMemberpm:ReducedRiskProductsMember2021-01-012021-06-300001413329pm:EasternEuropeSegmentMemberpm:ReducedRiskProductsMember2020-01-012020-06-300001413329pm:EasternEuropeSegmentMemberpm:ReducedRiskProductsMember2021-04-012021-06-300001413329pm:EasternEuropeSegmentMemberpm:ReducedRiskProductsMember2020-04-012020-06-300001413329pm:ReducedRiskProductsMemberpm:MiddleEastAfricaSegmentMember2021-01-012021-06-300001413329pm:ReducedRiskProductsMemberpm:MiddleEastAfricaSegmentMember2020-01-012020-06-300001413329pm:ReducedRiskProductsMemberpm:MiddleEastAfricaSegmentMember2021-04-012021-06-300001413329pm:ReducedRiskProductsMemberpm:MiddleEastAfricaSegmentMember2020-04-012020-06-300001413329pm:ReducedRiskProductsMemberpm:SouthSoutheastAsiaSegmentMember2021-01-012021-06-300001413329pm:ReducedRiskProductsMemberpm:SouthSoutheastAsiaSegmentMember2020-01-012020-06-300001413329pm:ReducedRiskProductsMemberpm:SouthSoutheastAsiaSegmentMember2021-04-012021-06-300001413329pm:ReducedRiskProductsMemberpm:SouthSoutheastAsiaSegmentMember2020-04-012020-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:ReducedRiskProductsMember2021-01-012021-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:ReducedRiskProductsMember2020-01-012020-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:ReducedRiskProductsMember2021-04-012021-06-300001413329pm:EastAsiaAustraliaSegmentMemberpm:ReducedRiskProductsMember2020-04-012020-06-300001413329pm:ReducedRiskProductsMemberpm:LatinAmericaCanadaSegmentMember2021-01-012021-06-300001413329pm:ReducedRiskProductsMemberpm:LatinAmericaCanadaSegmentMember2020-01-012020-06-300001413329pm:ReducedRiskProductsMemberpm:LatinAmericaCanadaSegmentMember2021-04-012021-06-300001413329pm:ReducedRiskProductsMemberpm:LatinAmericaCanadaSegmentMember2020-04-012020-06-300001413329pm:ReducedRiskProductsMember2021-01-012021-06-300001413329pm:ReducedRiskProductsMember2020-01-012020-06-300001413329pm:ReducedRiskProductsMember2021-04-012021-06-300001413329pm:ReducedRiskProductsMember2020-04-012020-06-300001413329country:SApm:MiddleEastAfricaSegmentMember2021-01-012021-06-300001413329country:SApm:MiddleEastAfricaSegmentMember2021-04-012021-06-30pm:manufacturer0001413329country:CApm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-27iso4217:CAD0001413329country:CApm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMemberpm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Member2015-05-272015-05-270001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMember2015-05-272015-05-27pm:plaintiff0001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMemberpm:AppellateRulingMember2015-10-012015-10-300001413329country:CApm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMemberpm:ImperialTobaccoLtd.Memberpm:AppellateRulingMember2015-10-012015-10-300001413329country:CApm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMemberpm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Member2019-03-012019-03-010001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMember2019-03-012019-03-010001413329country:CApm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMemberpm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Member2019-03-012019-03-010001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMemberpm:AppellateRulingMember2019-03-012019-03-010001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMemberpm:AppellateRulingMember2019-01-012019-03-310001413329country:CApm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-270001413329country:CApm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMemberpm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Member2015-05-272015-05-270001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMember2015-05-272015-05-270001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMemberus-gaap:JudicialRulingMember2019-03-012019-03-01pm:cigarette0001413329country:CAus-gaap:PendingLitigationMemberpm:AdamsMember2009-07-102009-07-100001413329country:CAus-gaap:PendingLitigationMemberpm:SuzanneJacklinMember2012-06-202012-06-20pm:litigationCase0001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2021-07-230001413329pm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2020-07-240001413329pm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2019-07-230001413329us-gaap:SubsequentEventMemberpm:SmokingAndHealthClassActionsMemberpm:CombustibleProductsMember2021-07-230001413329pm:SmokingAndHealthClassActionsMemberpm:CombustibleProductsMember2020-07-240001413329pm:SmokingAndHealthClassActionsMemberpm:CombustibleProductsMember2019-07-230001413329us-gaap:SubsequentEventMemberpm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2021-07-230001413329pm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2020-07-240001413329pm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2019-07-230001413329us-gaap:SubsequentEventMemberpm:CombustibleProductsMemberpm:LabelRelatedClassActionMember2021-07-230001413329pm:CombustibleProductsMemberpm:LabelRelatedClassActionMember2020-07-240001413329pm:CombustibleProductsMemberpm:LabelRelatedClassActionMember2019-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2021-07-230001413329pm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2020-07-240001413329pm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2019-07-230001413329us-gaap:SubsequentEventMemberpm:CombustibleProductsMemberpm:PublicCivilActionsMember2021-07-230001413329pm:CombustibleProductsMemberpm:PublicCivilActionsMember2020-07-240001413329pm:CombustibleProductsMemberpm:PublicCivilActionsMember2019-07-230001413329pm:CaseDecidedInFavorOfPlaintiffMember2021-06-300001413329pm:CasesRemainingOnAppealMember2021-06-30iso4217:ARS0001413329pm:HugoLespadaMemberpm:SmokingAndHealthIndividualActionsMembercountry:ARus-gaap:JudicialRulingMember2016-08-052016-08-050001413329pm:SmokingAndHealthIndividualActionsMembercountry:ARpm:ClaudiaMilanoMemberus-gaap:JudicialRulingMember2021-06-172021-06-170001413329us-gaap:SubsequentEventMemberpm:SmokingAndHealthIndividualActionsMembercountry:ARpm:ClaudiaMilanoMemberus-gaap:JudicialRulingMember2021-07-022021-07-020001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMembercountry:AR2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMembercountry:BR2021-07-230001413329country:CAus-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMembercountry:CLpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMembercountry:CN2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMembercountry:ITpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMembercountry:PHpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMembercountry:TR2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:ScotlandMemberpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMembercountry:US2021-07-230001413329us-gaap:SubsequentEventMemberpm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMembercountry:BR2021-07-230001413329country:CAus-gaap:SubsequentEventMemberpm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:HealthCareCostRecoveryActionsMembercountry:KRpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:HealthCareCostRecoveryActionsMembercountry:NGpm:CombustibleProductsMember2021-07-230001413329pm:HealthCareCostRecoveryActionsMembercountry:NGus-gaap:PendingLitigationMemberpm:TheAttorneyGeneralOfLagosStateMember2008-03-132008-03-130001413329pm:HealthCareCostRecoveryActionsMembercountry:NGus-gaap:PendingLitigationMemberpm:TheAttorneyGeneralOfKanoStateMember2007-05-092007-05-090001413329pm:HealthCareCostRecoveryActionsMembercountry:NGus-gaap:PendingLitigationMemberpm:TheAttorneyGeneralOfGombeStateMember2008-10-172008-10-170001413329pm:HealthCareCostRecoveryActionsMembercountry:NGus-gaap:PendingLitigationMemberpm:TheAttorneyGeneralOfOyoStateMember2007-05-252007-05-250001413329pm:TheAttorneyGeneralOfOgunStateMemberpm:HealthCareCostRecoveryActionsMembercountry:NGus-gaap:PendingLitigationMember2008-02-262008-02-26pm:patient0001413329pm:HealthCareCostRecoveryActionsMembercountry:KR2014-04-142014-04-140001413329us-gaap:SubsequentEventMembercountry:ITpm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMembercountry:CLpm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2021-07-230001413329us-gaap:SubsequentEventMemberpm:CombustibleProductsMembercountry:ARpm:PublicCivilActionsMember2021-07-230001413329country:VEus-gaap:SubsequentEventMemberpm:CombustibleProductsMemberpm:PublicCivilActionsMember2021-07-23iso4217:THB0001413329pm:OtherLitigationMemberus-gaap:PendingLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2016-01-182016-01-180001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2019-11-012019-11-300001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2017-01-262017-01-260001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2020-03-012020-03-31iso4217:KRW0001413329pm:OtherLitigationMembercountry:KRpm:TheSouthKoreanBoardOfAuditAndInspectionMember2016-11-012017-03-310001413329pm:OtherLitigationMembercountry:KRpm:TheSouthKoreanBoardOfAuditAndInspectionMember2016-11-012016-12-310001413329pm:OtherLitigationMembercountry:KRpm:TheSouthKoreanBoardOfAuditAndInspectionMember2017-01-012017-03-310001413329pm:OtherLitigationMembercountry:KRpm:TheSouthKoreanBoardOfAuditAndInspectionMember2020-01-012020-01-310001413329pm:OtherLitigationMembercountry:KRpm:TheSouthKoreanBoardOfAuditAndInspectionMember2020-06-012020-06-30iso4217:RUB0001413329pm:EasternEuropeMemberpm:TheMoscowTaxInspectorateforMajorTaxpayersAuditMemberpm:OtherLitigationMember2019-09-012019-09-300001413329pm:EasternEuropeMemberpm:TheMoscowTaxInspectorateforMajorTaxpayersAuditMemberpm:OtherLitigationMember2019-10-012019-12-31iso4217:SAR0001413329country:SApm:SaudiArabiaCustomsGeneralAuthorityCaseMemberpm:OtherLitigationMember2021-06-300001413329us-gaap:FinancialGuaranteeMemberpm:CanadianGovernmentMember2020-10-170001413329pm:PhilipMorrisInvestmentBVMemberpm:MedicagoIncMember2021-06-300001413329us-gaap:SubsequentEventMemberpm:PhilipMorrisInvestmentBVMemberpm:MedicagoIncMember2021-07-31pm:defendant0001413329srt:ScenarioForecastMember2021-01-012021-12-310001413329srt:MinimumMemberpm:UsDollarNotesMember2021-06-300001413329srt:MaximumMemberpm:UsDollarNotesMember2021-06-300001413329pm:UsDollarNotesMember2021-01-012021-06-300001413329pm:UsDollarNotesMember2021-06-300001413329pm:UsDollarNotesMember2020-12-310001413329srt:MinimumMemberpm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2021-06-300001413329srt:MaximumMemberpm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2021-06-300001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2021-01-012021-06-300001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2021-06-300001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2020-12-310001413329srt:MinimumMemberpm:ForeignCurrencyObligationsMemberpm:SwissFrancNotesMember2021-06-300001413329srt:MaximumMemberpm:ForeignCurrencyObligationsMemberpm:SwissFrancNotesMember2021-06-300001413329pm:ForeignCurrencyObligationsMemberpm:SwissFrancNotesMember2021-01-012021-06-300001413329pm:ForeignCurrencyObligationsMemberpm:SwissFrancNotesMember2021-06-300001413329pm:ForeignCurrencyObligationsMemberpm:SwissFrancNotesMember2020-12-310001413329us-gaap:NotesPayableOtherPayablesMemberpm:ForeignCurrencyObligationsMember2021-01-012021-06-300001413329us-gaap:NotesPayableOtherPayablesMemberpm:ForeignCurrencyObligationsMember2021-06-300001413329us-gaap:NotesPayableOtherPayablesMemberpm:ForeignCurrencyObligationsMember2020-12-310001413329us-gaap:FairValueInputsLevel1Member2021-06-300001413329us-gaap:FairValueInputsLevel2Member2021-06-300001413329pm:ThreeHundredSixtyFourDayRevolvingCreditExpiringFebruaryFirst2022Member2021-01-292021-01-290001413329pm:ThreeHundredSixtyFourDayRevolvingCreditExpiringFebruaryFirst2022Member2021-01-290001413329pm:ThreeHundredSixtyFourDayRevolvingCreditExpiringFebruaryFirst2022Member2021-06-300001413329pm:MultiYearRevolvingCreditFacilityExpiringOctober12022Member2021-06-300001413329pm:MultiYearRevolvingCreditFacilityExpiringFebruary102025Member2021-06-300001413329pm:MultiYearRevolvingCreditFacilityExpiringFebruary102025Member2021-01-290001413329pm:MultiYearRevolvingCreditFacilityExpiringFebruary102026Member2021-01-290001413329us-gaap:SubsequentEventMemberpm:MultiYearRevolvingCreditFacilityExpiringFebruary102026Member2021-07-020001413329us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001413329us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001413329us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300001413329us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300001413329us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001413329us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300001413329us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300001413329us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001413329us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300001413329pm:EquityMethodInvestmentGoodwillMember2021-06-300001413329pm:EquityMethodInvestmentGoodwillMember2020-12-310001413329srt:MinimumMember2021-01-012021-06-300001413329srt:MaximumMember2021-01-012021-06-3000014133292020-01-012020-12-310001413329pm:MegapolisMember2021-06-300001413329pm:EITAMember2021-06-300001413329pm:STAEMMember2021-06-300001413329pm:EITAMemberpm:STAEMMember2021-06-300001413329pm:ManagementEtDeveloppementDesActifsEtDesRessourcesHoldingMADARHoldingMemberpm:STAEMMember2021-06-300001413329pm:RothmansBensonAndHedgesInc.RBHMember2019-03-220001413329pm:PMMMemberpm:TTIMember2021-06-300001413329pm:IPMIndiaMember2021-06-300001413329pm:MegapolisMember2021-01-012021-06-300001413329pm:MegapolisMember2020-01-012020-06-300001413329pm:MegapolisMember2021-04-012021-06-300001413329pm:MegapolisMember2020-04-012020-06-300001413329pm:OtherRelatedPartyMember2021-01-012021-06-300001413329pm:OtherRelatedPartyMember2020-01-012020-06-300001413329pm:OtherRelatedPartyMember2021-04-012021-06-300001413329pm:OtherRelatedPartyMember2020-04-012020-06-300001413329pm:MegapolisMember2021-06-300001413329pm:MegapolisMember2020-12-310001413329pm:OtherRelatedPartyMember2021-06-300001413329pm:OtherRelatedPartyMember2020-12-310001413329pm:EastAsiaAndAustraliaMemberpm:PhilipMorrisKoreaMemberus-gaap:ContractTerminationMember2021-01-012021-03-310001413329pm:EastAsiaAndAustraliaMemberpm:PhilipMorrisKoreaMemberus-gaap:ContractTerminationMember2021-04-012021-06-30pm:employee0001413329pm:SwitzerlandRestructuringFinalPhasesMember2021-01-012021-06-300001413329us-gaap:EmployeeSeveranceMember2021-01-012021-06-300001413329us-gaap:EmployeeSeveranceMember2021-04-012021-06-300001413329pm:OrganizationalDesignOptimizationMember2021-06-300001413329pm:OrganizationalDesignOptimizationMemberus-gaap:EmployeeSeveranceMember2021-06-300001413329pm:AssetImpairmentMemberpm:OrganizationalDesignOptimizationMember2021-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberus-gaap:EuropeanUnionMember2021-01-012021-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberus-gaap:EuropeanUnionMember2020-01-012020-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberus-gaap:EuropeanUnionMember2021-04-012021-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberus-gaap:EuropeanUnionMember2020-04-012020-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-01-012020-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-04-012020-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-01-012020-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-04-012020-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberpm:SouthAndSoutheastAsiaMember2021-01-012021-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberpm:SouthAndSoutheastAsiaMember2020-01-012020-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberpm:SouthAndSoutheastAsiaMember2021-04-012021-06-300001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberpm:SouthAndSoutheastAsiaMember2020-04-012020-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-01-012020-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-04-012020-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-01-012021-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-01-012020-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-04-012021-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2020-04-012020-06-300001413329us-gaap:EmployeeSeveranceMember2020-01-012020-06-300001413329us-gaap:EmployeeSeveranceMember2020-04-012020-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:ContractTerminationMember2021-01-012021-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:ContractTerminationMember2020-01-012020-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:ContractTerminationMember2021-04-012021-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:ContractTerminationMember2020-04-012020-06-300001413329us-gaap:ContractTerminationMember2021-01-012021-06-300001413329us-gaap:ContractTerminationMember2020-01-012020-06-300001413329us-gaap:ContractTerminationMember2021-04-012021-06-300001413329us-gaap:ContractTerminationMember2020-04-012020-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberus-gaap:EuropeanUnionMember2021-01-012021-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberus-gaap:EuropeanUnionMember2020-01-012020-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberus-gaap:EuropeanUnionMember2021-04-012021-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberus-gaap:EuropeanUnionMember2020-04-012020-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-01-012021-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-01-012020-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-04-012021-06-300001413329pm:EasternEuropeMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-04-012020-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-01-012021-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-01-012020-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-04-012021-06-300001413329pm:MiddleEastAndAfricaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-04-012020-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberpm:SouthAndSoutheastAsiaMember2021-01-012021-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberpm:SouthAndSoutheastAsiaMember2020-01-012020-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberpm:SouthAndSoutheastAsiaMember2021-04-012021-06-300001413329us-gaap:OperatingSegmentsMemberpm:AssetImpairmentMemberpm:SouthAndSoutheastAsiaMember2020-04-012020-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-01-012021-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-01-012020-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-04-012021-06-300001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-04-012020-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-01-012021-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-01-012020-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2021-04-012021-06-300001413329pm:LatinAmericaAndCanadaMemberus-gaap:OperatingSegmentsMemberpm:AssetImpairmentMember2020-04-012020-06-300001413329pm:AssetImpairmentMember2021-01-012021-06-300001413329pm:AssetImpairmentMember2020-01-012020-06-300001413329pm:AssetImpairmentMember2021-04-012021-06-300001413329pm:AssetImpairmentMember2020-04-012020-06-300001413329srt:ScenarioForecastMember2021-07-012021-12-310001413329pm:AGSnusAktieselskabMember2021-05-310001413329pm:AGSnusAktieselskabMember2021-05-012021-05-310001413329us-gaap:OtherCurrentAssetsMemberpm:VecturaGroupPlcMemberus-gaap:SubsequentEventMember2021-07-31iso4217:GBP0001413329pm:VecturaGroupPlcMemberus-gaap:SubsequentEventMember2021-07-092021-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One) 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-33708
Philip Morris International Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3435103
(State or other jurisdiction of
    incorporation or organization)
(I.R.S. Employer
    Identification No.)
120 Park Avenue New York New York 10017
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (917) 663-2000
Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:
Title of each class                     Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PM New York Stock Exchange
2.900% Notes due 2021 PM21A New York Stock Exchange
2.625% Notes due 2022 PM22A New York Stock Exchange
2.375% Notes due 2022 PM22B New York Stock Exchange
2.500% Notes due 2022 PM22 New York Stock Exchange
2.500% Notes due 2022 PM22C New York Stock Exchange
2.625% Notes due 2023 PM23 New York Stock Exchange
2.125% Notes due 2023 PM23B New York Stock Exchange
3.600% Notes due 2023 PM23A New York Stock Exchange
2.875% Notes due 2024 PM24 New York Stock Exchange
2.875% Notes due 2024 PM24C New York Stock Exchange
0.625% Notes due 2024 PM24B New York Stock Exchange
3.250% Notes due 2024 PM24A New York Stock Exchange
2.750% Notes due 2025 PM25 New York Stock Exchange
3.375% Notes due 2025 PM25A New York Stock Exchange
2.750% Notes due 2026 PM26A New York Stock Exchange
Title of each class                     Trading Symbol(s) Name of each exchange on which registered
2.875% Notes due 2026 PM26 New York Stock Exchange
0.125% Notes due 2026 PM26B New York Stock Exchange
3.125% Notes due 2027 PM27 New York Stock Exchange
3.125% Notes due 2028 PM28 New York Stock Exchange
2.875% Notes due 2029 PM29 New York Stock Exchange
3.375% Notes due 2029 PM29A New York Stock Exchange
0.800% Notes due 2031 PM31 New York Stock Exchange
3.125% Notes due 2033 PM33 New York Stock Exchange
2.000% Notes due 2036 PM36 New York Stock Exchange
1.875% Notes due 2037 PM37A New York Stock Exchange
6.375% Notes due 2038 PM38 New York Stock Exchange
1.450% Notes due 2039 PM39 New York Stock Exchange
4.375% Notes due 2041 PM41 New York Stock Exchange
4.500% Notes due 2042 PM42 New York Stock Exchange
3.875% Notes due 2042 PM42A New York Stock Exchange
4.125% Notes due 2043 PM43 New York Stock Exchange
4.875% Notes due 2043 PM43A New York Stock Exchange
4.250% Notes due 2044 PM44 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ        No  ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  þ        No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer    þ                        Accelerated filer              
Non-accelerated filer                             Smaller reporting company    ☐
                                    Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  þ
At July 22, 2021, there were 1,558,540,992 shares outstanding of the registrant’s common stock, no par value per share.
1

PHILIP MORRIS INTERNATIONAL INC.
TABLE OF CONTENTS
 
    Page No.
PART I -
Item 1.
Condensed Consolidated Statements of Earnings for the
Six Months Ended June 30, 2021 and 2020
3
Three Months Ended June 30, 2021 and 2020
4
Condensed Consolidated Statements of Comprehensive Earnings for the
Six Months Ended June 30, 2021 and 2020
5
Three Months Ended June 30, 2021 and 2020
6
Condensed Consolidated Balance Sheets at
June 30, 2021 and December 31, 2020
7 8
Condensed Consolidated Statements of Cash Flows for the
Six Months Ended June 30, 2021 and 2020
9 – 10
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the
Six Months Ended June 30, 2021 and 2020
Three Months Ended June 30, 2021 and 2020
13 45
Item 2.
46 99
Item 4.
PART II -
Item 1.
Item 1A.
Item 2.
Item 6.

In this report, “PMI,” “we,” “us” and “our” refer to Philip Morris International Inc. and its subsidiaries.

Trademarks and service marks in this report are the registered property of, or licensed by, the subsidiaries of Philip Morris International Inc. and are italicized.
2

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
  For the Six Months Ended June 30,
  2021 2020
Revenues including excise taxes $ 39,776  $ 36,072 
Excise taxes on products 24,597  22,268 
Net revenues (Note 8) 15,179  13,804 
Cost of sales 4,627  4,581 
Gross profit 10,552  9,223 
Marketing, administration and research costs (Note 16) 3,942  3,666 
Amortization of intangibles 37  37 
Operating income 6,573  5,520 
Interest expense, net 328  291 
Pension and other employee benefit costs (Note 3) 55  45 
Earnings before income taxes 6,190  5,184 
Provision for income taxes 1,343  1,124 
Equity investments and securities (income)/loss, net (46) 24 
Net earnings $ 4,893  $ 4,036 
Net earnings attributable to noncontrolling interests 303  263 
Net earnings attributable to PMI $ 4,590  $ 3,773 

Per share data (Note 6):
Basic earnings per share $ 2.94  $ 2.42 
Diluted earnings per share $ 2.93  $ 2.42 









See notes to condensed consolidated financial statements.
3

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
  For the Three Months Ended June 30,
  2021 2020
Revenues including excise taxes $ 20,421  $ 17,819 
Excise taxes on products 12,827  11,168 
Net revenues (Note 8) 7,594  6,651 
Cost of sales 2,353  2,179 
Gross profit 5,241  4,472 
Marketing, administration and research costs (Note 16) 2,093  1,722 
Amortization of intangibles 19  19 
Operating income 3,129  2,731 
Interest expense, net 161  162 
Pension and other employee benefit costs (Note 3) 27  22 
Earnings before income taxes 2,941  2,547 
Provision for income taxes 646  528 
Equity investments and securities (income)/loss, net (3) (30)
Net earnings 2,298  2,049 
Net earnings attributable to noncontrolling interests 126  102 
Net earnings attributable to PMI $ 2,172  $ 1,947 

Per share data (Note 6):
Basic earnings per share $ 1.39  $ 1.25 
Diluted earnings per share $ 1.39  $ 1.25 








See notes to condensed consolidated financial statements.
4

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)

For the Six Months Ended June 30,
2021 2020
Net earnings $ 4,893  $ 4,036 
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $(25) in 2021 and $(40) in 2020
227  (785)

Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes of $(5) in 2021 and $0 in 2020
20  — 
Amortization of net losses, prior service costs and net transition costs, net of income taxes of $(36) in 2021 and $(34) in 2020
162  149 

Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $(12) in 2021 and $1 in 2020
77  (6)
(Gains) losses transferred to earnings, net of income taxes of $0 in 2021 and $2 in 2020
(15)
Total other comprehensive earnings (losses) 488  (657)
Total comprehensive earnings 5,381  3,379 
Less comprehensive earnings attributable to:
Noncontrolling interests 275  252 
Comprehensive earnings attributable to PMI $ 5,106  $ 3,127 


















See notes to condensed consolidated financial statements.
5

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
For the Three Months Ended June 30,
2021 2020
Net earnings $ 2,298  $ 2,049 
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $60 in 2021 and $56 in 2020
797 

Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes of $(5) in 2021 and $0 in 2020
20  — 
Amortization of net losses, prior service costs and net transition costs, net of income taxes of $(18) in 2021 and $(17) in 2020
81  75 

Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $2 in 2021 and $6 in 2020
(32)
(Gains) losses transferred to earnings, net of income taxes of $0 in 2021 and $1 in 2020
(19) (6)
Total other comprehensive earnings (losses) 87  834 
Total comprehensive earnings
2,385  2,883 
Less comprehensive earnings attributable to:
Noncontrolling interests 132  171 
Comprehensive earnings attributable to PMI $ 2,253  $ 2,712 
















See notes to condensed consolidated financial statements.
6

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
 
June 30,
2021
December 31,
2020
ASSETS
Cash and cash equivalents $ 4,915  $ 7,280 
Trade receivables (less allowances of $57 in 2021 and $23 in 2020)
3,536  2,905 
Other receivables (less allowances of $37 in 2021 and $38 in 2020)
909  856 

Inventories:
Leaf tobacco 1,918  2,063 
Other raw materials 1,950  1,712 
Finished product 4,822  5,816 
8,690  9,591 
Other current assets 693  860 

Total current assets
18,743  21,492 

Property, plant and equipment, at cost
14,615  14,909 
Less: accumulated depreciation 8,640  8,544 
5,975  6,365 
Goodwill (Note 4) 5,842  5,964 
Other intangible assets, net (Note 4) 1,958  2,019 
Equity investments (Note 12) 4,633  4,798 
Deferred income taxes 1,112  1,410 
Other assets (less allowances of $22 in 2021 and $22 in 2020)
2,423  2,767 
TOTAL ASSETS $ 40,686  $ 44,815 









See notes to condensed consolidated financial statements.
Continued
7

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share data)
(Unaudited)
 
June 30,
2021
December 31,
2020
LIABILITIES
Short-term borrowings (Note 10) $ 136  $ 244 
Current portion of long-term debt (Note 10) 1,608  3,124 
Accounts payable 2,630  2,780 
Accrued liabilities:
Marketing and selling 722  782 
Taxes, except income taxes 5,244  6,403 
Employment costs 1,016  1,189 
Dividends payable 1,889  1,880 
Other 1,859  2,122 
Income taxes 780  1,091 
Total current liabilities 15,884  19,615 

Long-term debt (Note 10)
27,414  28,168 
Deferred income taxes 505  684 
Employment costs 4,054  4,470 
Income taxes and other liabilities 2,029  2,509 
Total liabilities 49,886  55,446 

Contingencies (Note 8)

STOCKHOLDERS’ (DEFICIT) EQUITY

Common stock, no par value
   (2,109,316,331 shares issued in 2021 and 2020)
—  — 
Additional paid-in capital 2,143  2,105 
Earnings reinvested in the business 32,465  31,638 
Accumulated other comprehensive losses (10,665) (11,181)
23,943  22,562 
Less: cost of repurchased stock
   (550,736,681 and 551,942,600 shares in 2021 and 2020, respectively)
35,056  35,129 
Total PMI stockholders’ deficit (11,113) (12,567)
Noncontrolling interests 1,913  1,936 
Total stockholders’ deficit (9,200) (10,631)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $ 40,686  $ 44,815 





See notes to condensed consolidated financial statements.
8

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
 
  For the Six Months Ended June 30,
  2021 2020
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings $ 4,893  $ 4,036 
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization 484  470 
Deferred income tax (benefit) provision (94)
Asset impairment and exit costs, net of cash paid (Note 16) (26) (2)
Cash effects of changes in:
Receivables, net (627) (338)
Inventories 767  (20)
Accounts payable (16) (164)
Accrued liabilities and other current assets (940) (780)
Income taxes (459) (233)
Pension plan contributions (197) (52)
Other 184  213 
Net cash provided by operating activities 4,065  3,036 
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures (307) (310)
Purchases of businesses, net of acquired cash (Note 17) (27) — 
Equity investments —  (3)
Net investment hedges 147  174 
Other 59 
Net cash used in investing activities (128) (134)
 















See notes to condensed consolidated financial statements.

Continued
9

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
 
  For the Six Months Ended June 30,
  2021 2020
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
Short-term borrowing activity by original maturity:
    Net issuances (repayments) - maturities of 90 days or less $ (108) $ (75)
    Issuances - maturities longer than 90 days —  45 
Long-term debt proceeds —  2,230 
Long-term debt repaid (1,979) (3,641)
Dividends paid (3,752) (3,658)
Payments to noncontrolling interests and Other
(284) (404)
Net cash used in financing activities (6,123) (5,503)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (179) (57)
Cash, cash equivalents and restricted cash (1):
Increase (Decrease) (2,365) (2,658)
Balance at beginning of period 7,285  6,865 
Balance at end of period $ 4,920  $ 4,207 

(1) The amounts for cash and cash equivalents shown above include restricted cash of $5 million and $7 million as of June 30, 2021 and 2020, respectively, and $5 million and $4 million as of December 31, 2020 and 2019, respectively, which were included in other current assets in the condensed consolidated balance sheets.






See notes to condensed consolidated financial statements.
10

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Six Months Ended June 30, 2021 and 2020
(in millions of dollars, except per share amounts)
(Unaudited)
  PMI Stockholders’ (Deficit) Equity    
  Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock
Noncontrolling
Interests
Total
Balances, January 1, 2020 $ —  $ 2,019  $ 30,987  $ (9,363) $ (35,220) $ 1,978  $ (9,599)
Net earnings 3,773  263  4,036 
Other comprehensive earnings (losses), net of income taxes (646) (11) (657)
Issuance of stock awards 85  94 
Dividends declared ($2.34 per share)
(3,657) (3,657)
Payments to noncontrolling interests (339) (339)
Other 16  (14)
Balances, June 30, 2020 $ —  $ 2,044  $ 31,103  $ (10,009) $ (35,135) $ 1,877  $ (10,120)
Balances, January 1, 2021 $ —  $ 2,105  $ 31,638  $ (11,181) $ (35,129) $ 1,936  $ (10,631)
Net earnings 4,590  303  4,893 
Other comprehensive earnings (losses), net of income taxes 516  (28) 488 
Issuance of stock awards 38  73  111 
Dividends declared ($2.40 per share)
(3,763) (3,763)
Payments to noncontrolling interests (298) (298)
Balances, June 30, 2021 $ —  $ 2,143  $ 32,465  $ (10,665) $ (35,056) $ 1,913  $ (9,200)




See notes to condensed consolidated financial statements.
11

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Three Months Ended June 30, 2021 and 2020
(in millions of dollars, except per share amounts)
(Unaudited)
  PMI Stockholders’ (Deficit) Equity    
  Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock
Noncontrolling
Interests
Total
Balances, April 1, 2020 $ —  $ 1,992  $ 30,984  $ (10,774) $ (35,146) $ 1,881  $ (11,063)
Net earnings     1,947      102  2,049 
Other comprehensive earnings (losses), net of income taxes       765    69  834 
Issuance of stock awards   34      11    45 
Dividends declared ($1.17 per share)
    (1,828)       (1,828)
Payments to noncontrolling interests           (157) (157)
Other   18        (18) — 
Balances, June 30, 2020 $ —  $ 2,044  $ 31,103  $ (10,009) $ (35,135) $ 1,877  $ (10,120)
Balances, April 1, 2021 $ —  $ 2,080  $ 32,178  $ (10,746) $ (35,060) $ 1,974  $ (9,574)
Net earnings     2,172      126  2,298 
Other comprehensive earnings (losses), net of income taxes       81    87 
Issuance of stock awards   63        67 
Dividends declared ($1.20 per share)
    (1,885)       (1,885)
Payments to noncontrolling interests           (193) (193)
Balances, June 30, 2021 $ —  $ 2,143  $ 32,465  $ (10,665) $ (35,056) $ 1,913  $ (9,200)


See notes to condensed consolidated financial statements.
12

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 1. Background and Basis of Presentation:

Background

Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United States of America), whose subsidiaries and affiliates and their licensees are engaged in the manufacture and sale of cigarettes and other nicotine-containing products, including reduced-risk products, in markets outside of the United States of America. In addition, PMI ships versions of its Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration ("FDA") to Altria Group, Inc., for sale in the United States under license. Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries.

Reduced-risk products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization.

"Platform 1" is the term PMI uses to refer to PMI’s reduced-risk product that uses a precisely controlled heating device into which a specially designed and proprietary tobacco unit is inserted and heated to generate an aerosol.

Basis of Presentation

The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a consistent basis. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not necessarily indicative of results that may be expected for the entire year.

Certain prior years' amounts have been reclassified to conform with the current year's presentation. The changes did not have a material impact on PMI's consolidated financial position, results of operations or cash flows in any of the periods presented.

These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report on Form 10-K for the year ended December 31, 2020.


13

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 2. Stock Plans:

In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Performance Incentive Plan (the “2017 Plan”). Under the 2017 Plan, PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity awards. Up to 25 million shares of PMI’s common stock may be issued under the 2017 Plan. At June 30, 2021, shares available for grant under the 2017 Plan were 14,867,021.

In May 2017, PMI’s shareholders also approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the “2017 Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-Employee Directors Plan. At June 30, 2021, shares available for grant under the plan were 914,413.

Restricted share unit (RSU) awards

During the six months ended June 30, 2021 and 2020, shares granted to eligible employees and the weighted-average grant date fair value per share related to RSU awards were as follows:
Number of
Shares
Granted
Weighted-Average Grant Date Fair Value Per RSU Award Granted
2021 1,981,480  $  81.91 
2020 1,692,650  $  85.91 

Compensation expense related to RSU awards was as follows:
Compensation Expense Related to RSU Awards
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 $ 73  $ 33 
2020 $ 68  $ 29 

As of June 30, 2021, PMI had $211 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58.

During the six months ended June 30, 2021, 1,106,129 RSU awards vested. The grant date fair value of all the vested awards was approximately $108 million. The total fair value of RSU awards that vested during the six months ended June 30, 2021 was approximately $96 million.

Performance share unit (PSU) awards

During the six months ended June 30, 2021 and 2020, PMI granted PSU awards to certain executives. The PSU awards require the achievement of certain performance factors, which are predetermined at the time of grant, typically over a three-year performance cycle. The performance metrics for such PSU's granted during the six months ended June 30, 2021 and 2020 consisted of PMI's Total Shareholder Return ("TSR") relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and PMI’s performance against specific measures of PMI’s transformation, defined as net revenues from PMI's RRPs and any other non-combustible products as a percentage of PMI's total net revenues in the last year of the performance cycle (30% weight).

The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum percentage of 200. Each such vested PSU entitles the participant to one share
14

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
of common stock. An aggregate weighted PSU performance factor of 100 will result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the accumulated dividends paid on common stock during the performance cycle for the number of shares earned.

During the six months ended June 30, 2021 and 2020, shares granted to eligible employee and the grant date fair value per share related to PSU awards were as follows:
Number of Shares Granted Grant Date 
Fair Value Subject to Other Performance Factors
Grant Date 
Fair Value Subject to TSR Performance Factor
(Per Share) (Per Share)
2021 574,410  $  81.86  $  106.93 
2020 671,220  $  86.04  $ 80.36 

The grant date fair value of the PSU awards subject to the other performance factors was determined by using the average of the high and low market price of PMI’s stock at the date of the grant. The grant date fair value of the PSU market based awards subject to the TSR performance factor was determined by using the Monte Carlo simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance factor:
2021 2020
Risk-free interest rate (a)
0.2  % 1.4  %
Expected volatility (b)
31.7  % 23.5  %
(a) Based on the U.S. Treasury yield curve.
(b) Determined using the observed historical volatility.

Compensation expense related to PSU awards was as follows:
Compensation Expense Related to PSU Awards
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 $  46  $  34 
2020 $  32  $  9 

As of June 30, 2021, PMI had $71 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the performance cycle of the awards, or upon death, disability or reaching the age of 58.

During the six months ended June 30, 2021, 189,839 PSU awards vested. The grant date fair value of all the vested awards was approximately $21 million. The total fair value of PSU awards that vested during the six months ended June 30, 2021 was approximately $16 million.

Note 3. Benefit Plans:

Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed by local statutory requirements. In addition, PMI provides health care and other benefits to substantially all U.S. retired employees and certain non-U.S. retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans.

15

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
  For the Six Months Ended June 30, For the Three Months Ended June 30,
(in millions) 2021 2020 2021 2020
Net pension costs (income) $ (2) $ (8) $ (1) $ (4)
Net postemployment costs 53  49  25  24 
Net postretirement costs
Total pension and other employee benefit costs $ 55  $ 45  $ 27  $ 22 

Pension Plans

Components of Net Periodic Benefit Cost

Net periodic pension cost consisted of the following:
 
Pension (1)
  For the Six Months Ended June 30, For the Three Months Ended June 30,
(in millions) 2021 2020 2021 2020
Service cost $ 147  $ 130  $ 72  $ 65 
Interest cost 25  35  12  18 
Expected return on plan assets (186) (173) (91) (87)
Amortization:
Net loss 158  129  78  64 
Prior service cost — 
Net periodic pension cost $ 145  $ 122  $ 71  $ 61 
(1) Primarily non-U.S. based defined benefit retirement plans.

Employer Contributions
PMI makes, and plans to make, contributions, to the extent that they are tax deductible and to meet specific funding requirements of its funded pension plans. Employer contributions of $197 million were made to the pension plans during the six months ended June 30, 2021. Currently, PMI anticipates making additional contributions during the remainder of 2021 of approximately $78 million to its pension plans, based on current tax and benefit laws. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on pension assets, or changes in interest and currency rates.

Note 4. Goodwill and Other Intangible Assets, net:

The movements in goodwill were as follows:
(in millions) European Union Eastern Europe Middle East & Africa South & Southeast Asia East Asia & Australia Latin America & Canada Total
Balances, December 31, 2020 $ 1,434  $ 317  $ 86  $ 2,915  $ 559  $ 653  $ 5,964 
Changes due to:
Acquisitions 29  —  —  —  —  —  29 
Currency (30) (8) (86) (17) (12) (151)
Balances, June 30, 2021 $ 1,433  $ 309  $ 88  $ 2,829  $ 542  $ 641  $ 5,842 

At June 30, 2021, goodwill primarily reflects PMI’s acquisitions in Colombia, Greece, Indonesia, Mexico, Pakistan and Serbia, as well as the business combination in the Philippines.
16

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

The increase in goodwill from acquisitions was due to the preliminary purchase price allocation of AG Snus Aktieselskab ("AG Snus"), a Danish based company, and it's Swedish subsidiary Tobacco House of Sweden AB, fully owned by AG Snus. For further details, see Note 17. Acquisitions.

Details of other intangible assets were as follows:
June 30, 2021 December 31, 2020
(in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net
Non-amortizable intangible assets $ 1,261  $ 1,261  $ 1,289  $ 1,289 
Amortizable intangible assets:
Trademarks 12 years 1,233  $ 621  612  1,233  $ 594  639 
Distribution networks 7 years 113  79  34  115  78  37 
Other* 8 years 105  54  51  104  50  54 
Total other intangible assets $ 2,712  $ 754  $ 1,958  $ 2,741  $ 722  $ 2,019 
* Primarily includes intellectual property rights

Non-amortizable intangible assets substantially consist of trademarks from PMI’s acquisitions in Indonesia and Mexico. The decrease since December 31, 2020 was due to currency movements of ($28 million).

The decrease in the gross carrying amount of amortizable intangible assets from December 31, 2020, was mainly due to currency movements of ($8 million), partially offset by the preliminary purchase price allocation of AG Snus trademarks in the amount of $7 million. For further details, see Note 17. Acquisitions.

The change in the accumulated amortization from December 31, 2020, was mainly due to the 2021 amortization of $37 million, partially offset by currency movements of ($5 million).

Amortization expense for each of the next five years is estimated to be $75 million or less, assuming no additional transactions occur that require the amortization of intangible assets.

During the second quarter of 2021, PMI completed its annual review of goodwill and non-amortizable intangible assets for potential impairment, and no impairment charges were required as a result of this review.

17

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 5. Financial Instruments:

Overview

PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes certain financial instruments to manage foreign currency and interest rate exposures. Derivative financial instruments are used by PMI principally to reduce exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the consolidated balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Financial instruments qualifying for hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings.

PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Both foreign exchange contracts and interest rate contracts are collectively referred to as derivative contracts ("derivative contracts"). The primary currencies to which PMI is exposed include the Euro, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble and Swiss franc. At June 30, 2021, PMI had contracts with aggregate notional amounts of $22.7 billion of which $3.5 billion related to cash flow hedges, $7.6 billion related to hedges of net investments in foreign operations and $11.6 billion related to other derivatives that primarily offset currency exposures on intercompany financing.

18

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020, were as follows:
  Derivative Assets Derivative Liabilities
  Fair Value Fair Value
At At At At
(in millions) Balance Sheet Classification June 30, 2021 December 31, 2020 Balance Sheet Classification June 30, 2021 December 31, 2020
Derivative contracts designated as hedging instruments Other current assets $ 187  $ 130  Other accrued liabilities $ 92  $ 241 
Other assets —  Income taxes and other liabilities 424  605 
Derivative contracts not designated as hedging instruments 
Other current assets 
104  46  Other accrued liabilities 28  207 
Other assets —  —  Income taxes and other liabilities 38  57 
Total gross amount derivatives contracts presented in the condensed consolidated balance sheets   $ 291  $ 182    $ 582  $ 1,110 
Gross amounts not offset in the condensed consolidated balance sheets
Finance instruments (140) (156) (140) (156)
Cash collateral received/pledged (126) (23) (425) (892)
Net amount $ 25  $ $ 17  $ 62 

PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates. PMI’s derivative contracts have been classified within Level 2 at June 30, 2021 and December 31, 2020.




















19

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the six months ended June 30, 2021 and 2020, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows:
(pre-tax, in millions) For the Six Months Ended June 30,
Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings
Classification of Gain/(Loss)
on Derivatives
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings
2021 2020 2021 2020 2021 2020
Derivative contracts designated as hedging instruments:
Cash flow hedges $ 89  $ (7)
Net revenues $ 17  $
Cost of sales — 
Marketing, administration and research costs (12) 11 
Interest expense, net (7) (5)
Net investment hedges (a)
192  269 
Interest expense, net (b)
$ 82  $ 104 
Derivative contracts not designated as hedging instruments: Interest expense, net 25  48 
Marketing, administration and research costs (c)
196  (63)
Total $ 281  $ 262  $ (2) $ 17  $ 303  $ 89 
(a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar
(b) Represent the gains for amounts excluded from the effectiveness testing
(c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates substantially offset the (losses) and gains generated by the underlying intercompany and third-party loans being hedged















20

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the three months ended June 30, 2021 and 2020, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows:
(pre-tax, in millions) For the Three Months Ended June 30,
Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings
Classification of Gain/(Loss)
on Derivatives
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings
2021 2020 2021 2020 2021 2020
Derivative contracts designated as hedging instruments:
Cash flow hedges $ (1) $ (38)
Net revenues $ 17  $
Cost of sales — 
Marketing, administration and research costs
Interest expense, net (4) (3)
Net investment hedges (a)
(126) (138)
Interest expense, net (b)
$ 40  $ 48 
Derivative contracts not designated as hedging instruments: Interest expense, net 14  14 
Marketing, administration and research costs (c)
(91) (92)
Total $ (127) $ (176) $ 19  $ $ (37) $ (30)

(a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar
(b) Represent the gains for amounts excluded from the effectiveness testing
(c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates substantially offset the (losses) and gains generated by the underlying intercompany and third-party loans being hedged

Cash Flow Hedges

PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to certain forecasted transactions. Gains and losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses until the underlying hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of June 30, 2021, PMI has hedged forecasted transactions for periods not exceeding the next twelve months with the exception of one derivative contract that expires in May 2024. The impact of these hedges is primarily included in operating cash flows on PMI’s condensed consolidated statements of cash flows.

Hedges of Net Investments in Foreign Operations

PMI designates derivative contracts and certain foreign currency denominated debt instruments as net investment hedges, primarily of its Euro net assets. For the six months ended June 30, 2021 and 2020, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $110 million and $(103) million, respectively. For the three months ended June 30, 2021 and 2020, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $(71) million and $(98) million, respectively. The premiums paid for, and settlements of, net investment hedges are included in investing cash flows on PMI’s condensed consolidated statements of cash flows.

21

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Derivatives

PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain subsidiaries, and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses) relating to these contracts are reported in PMI’s condensed consolidated statements of earnings.
Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses

Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
  2021 2020 2021 2020
Gain/(loss) as beginning of period $ (85) $ $ 12  $ 20 
Derivative (gains)/losses transferred to earnings (15) (19) (6)
Change in fair value 77  (6) (32)
Gain/(loss) as of June 30, $ (6) $ (18) $ (6) $ (18)

At June 30, 2021, PMI expects $26 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings impact of the respective hedged transactions.
Contingent Features
PMI’s derivative instruments do not contain contingent features.
Credit Exposure and Credit Risk
PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as counterparties.

Note 6. Earnings Per Share:
Basic and diluted earnings per share (“EPS”) were calculated using the following:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
  2021 2020 2021 2020
Net earnings attributable to PMI $ 4,590  $ 3,773  $ 2,172  $ 1,947 
Less distributed and undistributed earnings attributable to share-based payment awards
14  10 
Net earnings for basic and diluted EPS $ 4,576  $ 3,763  $ 2,166  $ 1,942 
Weighted-average shares for basic EPS 1,558  1,557  1,558  1,558 
Plus contingently issuable performance stock units (PSUs) —  — 
Weighted-average shares for diluted EPS 1,560  1,557  1,560  1,558 

Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are included in PMI’s earnings per share calculation pursuant to the two-class method.
22

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

For the 2021 and 2020 computations, there were no antidilutive stock awards.

Note 7. Segment Reporting:

PMI’s subsidiaries and affiliates are engaged in the manufacture and sale of cigarettes and other nicotine-containing products, including RRPs, in markets outside of the United States of America. In addition, PMI ships versions of its Platform 1 device and its consumables authorized by the FDA to Altria Group, Inc. for sale in the United States under license. Operating segments for PMI are organized by geographic region and managed by segment managers who are responsible for the operating and financial results of the regions inclusive of all product categories sold in the region. PMI’s operating segments are the European Union; Eastern Europe; Middle East & Africa; South & Southeast Asia; East Asia & Australia; and Latin America & Canada. PMI records net revenues and operating income to its segments based upon the geographic area in which the customer resides. Revenues from shipments of Platform 1 devices, heated tobacco units and accessories to Altria Group, Inc. for sale under license in the United States are included in net revenues of the Latin America & Canada segment.

In July 2021, the Latin America & Canada operating segment was renamed as the Americas operating segment.

PMI’s chief operating decision maker evaluates segment performance and allocates resources based on regional operating income, which includes results from all product categories sold in each region.

PMI disaggregates its net revenue from contracts with customers by both geographic location and product category for each of PMI's six operating segments, as PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.

Segment data were as follows:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 2020 2021 2020
Net revenues:
European Union $ 6,058  $ 5,010  $ 3,149  $ 2,475 
Eastern Europe 1,691  1,571  895  783 
Middle East & Africa 1,361  1,580  560  704 
South & Southeast Asia 2,219  2,140  1,046  889 
East Asia & Australia 2,986  2,687  1,514  1,432 
Latin America & Canada 864  816  430  368 
Net revenues $ 15,179  $ 13,804  $ 7,594  $ 6,651 
Operating income:
European Union $ 3,131  $ 2,336  $ 1,641  $ 1,178 
Eastern Europe 575  365  314  266 
Middle East & Africa 351  558  16  237 
South & Southeast Asia 860  888  331  289 
East Asia & Australia 1,410  1,155  715  669 
Latin America & Canada 246  218  112  92 
Operating income $ 6,573  $ 5,520  $ 3,129  $ 2,731 


23

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

PMI's net revenues by product category were as follows:
(in millions) For the Six Months Ended June 30, For the Three Months Ended June 30,
2021 2020 2021 2020
Net revenues:
Combustible products:
European Union $ 4,113  $ 3,855  $ 2,162  $ 1,945 
Eastern Europe 1,047  1,045  555  522 
Middle East & Africa 1,307  1,528  527  696 
South & Southeast Asia 2,216  2,140  1,045  889 
East Asia & Australia 1,259  1,272  611  630 
Latin America & Canada 840  803  418  363 
Total combustible products $ 10,781  $ 10,643  $ 5,318  $ 5,045 
Reduced-risk products:
European Union $ 1,945  $ 1,155  $ 987  $ 530 
Eastern Europe 644  526  340  261 
Middle East & Africa 54  52  33 
South & Southeast Asia —  — 
East Asia & Australia 1,727  1,415  903  802 
Latin America & Canada 24  13  12 
Total reduced-risk products $ 4,398  $ 3,161  $ 2,276  $ 1,606 
Total PMI net revenues $ 15,179  $ 13,804  $ 7,594  $ 6,651 
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.

Items affecting the comparability of results from operations were as follows:

Asset impairment and exit costs - See Note 16. Asset Impairment and Exit Costs for a breakdown of these costs by segment for the six months and three months ended June 30, 2021 and 2020.
Saudi Arabia customs assessments - See Note 8. Contingencies for the details of the $246 million reduction in net revenues of combustible products included in the Middle East & Africa segment for the six months and three months ended June 30, 2021.

Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and cigarillos and do not include reduced-risk products.

Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's heated tobacco units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include PMI's e-vapor products.


24

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 8. Contingencies:
Tobacco-Related Litigation
Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend, as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for PMI.
It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending tobacco-related litigation could encourage the commencement of additional litigation.
Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Brazil, Canada and Nigeria, range into the billions of U.S. dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. Much of the tobacco-related litigation is in its early stages, and litigation is subject to uncertainty. However, as discussed below, we have to date been largely successful in defending tobacco-related litigation.
We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 8. Contingencies, while it is reasonably possible that an unfavorable outcome in a case may occur, after assessing the information available to it (i) management has not concluded that it is probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of loss for any of the pending tobacco-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for unfavorable outcomes in these cases, if any. Legal defense costs are expensed as incurred.
It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended. However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.    
CCAA Proceedings and Stay of Tobacco-Related Cases Pending in Canada
As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson & Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA order made by the Ontario Superior Court on March 22, 2019, authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course after the CCAA filing, including obligations to employees, vendors, and suppliers. As further described in Item 8, Note 20. Deconsolidation of RBH of PMI's Annual Report on Form 10-K for the year ended December 31, 2020, RBH's financial results have been deconsolidated from our consolidated financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30, 2021, of all tobacco-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria), namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented below under the caption “Stayed Litigation — Canada.” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation, it is anticipated that the court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau and the Blais cases so long as the comprehensive stay of all tobacco-related litigation in Canada remains in effect and that the time period to file the application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases were incorrect, the CCAA proceedings will provide a forum for
25

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
RBH to seek resolution through a plan of arrangement or compromise of all tobacco-related litigation pending in Canada. It is not possible to predict the resolution of the underlying legal proceedings or the length of the CCAA process.

Stayed Litigation — Canada

Smoking and Health Litigation — Canada

In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in November 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiffs, an anti-smoking organization and an individual smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain smoking-related diseases. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and found that the class members’ compensatory damages totaled approximately CAD 15.5 billion, including pre-judgment interest (approximately $12.3 billion). The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion, including pre-judgment interest (approximately $2.5 billion)). In addition, the trial court awarded CAD 90,000 (approximately $71,600) in punitive damages, allocating CAD 30,000 (approximately $23,900) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $180 million) to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco Canada Ltd. to furnish security totaling CAD 758 million (approximately $603 million) in installments through June 2017. JTI Macdonald Corp. was not required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal.

On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion including interest (approximately $10.7 billion) due to the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH (approximately CAD 2.7 billion, including pre-judgment interest (approximately $2.1 billion)). The Court of Appeal upheld the trial court’s findings that defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais case, approximately CAD 1.1 billion (approximately $875 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD 257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax, as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment.

In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants.  The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $104 million) in punitive damages, allocating CAD 46 million (approximately $37 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD 57 million including interest (approximately $45 million) to RBH. See the Blais description above and Item 8, Note 20. Deconsolidation of RBH in PMI's Annual Report on Form 10-K for the year ended December 31, 2020 for further detail concerning the security order pertaining to both Létourneau and Blais cases and the impact of the decision on PMI’s financial statements.
26

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on several grounds including the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking; (ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to all class members given the individual differences between class members.
In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada, filed June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products.
In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada, filed July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, emphysema, heart disease, or cancer, as well as restitution of profits.
In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia, Canada, filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products.
In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have not been properly served with the complaint.
In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed.

In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim.

In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised
27

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as restitution of profits.

Health Care Cost Recovery Litigation — Canada
In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting from a “tobacco related wrong.”
In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of Justice, Toronto, Canada, filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, St. Johns, Canada, filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec, Canada, filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench Alberta, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges, Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada, filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench, Judicial Centre of Saskatchewan, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws enacted in several other Canadian
28

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada, filed September 10, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”

In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Nova Scotia, Canada, filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
__________
The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as of July 23, 2021, July 24, 2020 and July 23, 2019:¹
Type of Case Number of Cases Pending as of July 23, 2021 Number of Cases Pending as of July 24, 2020 Number of Cases Pending as of July 23, 2019
Individual Smoking and Health Cases 44 44 52
Smoking and Health Class Actions 9 10 10
Health Care Cost Recovery Actions 17 17 17
Label-Related Class Actions 1
Individual Label-Related Cases 4 5 6
Public Civil Actions 2 2 2

Since 1995, when the first tobacco-related litigation was filed against a PMI entity, 515 Smoking and Health, Label-Related, Health Care Cost Recovery, and Public Civil Actions in which we and/or one of our subsidiaries and/or indemnitees were a defendant have been terminated in our favor. Fourteen cases have had decisions in favor of plaintiffs. Ten of these cases have subsequently reached final resolution in our favor and four remain on appeal.

The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff:




______
¹ Includes cases pending in Canada.


29

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
May 27, 2015    Canada/Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais
   Class Action   
On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Blais class on liability and found the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $12.3 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion including pre-judgment interest (approximately $2.5 billion)). The trial court awarded CAD 90,000 (approximately $71,600) in punitive damages, allocating CAD 30,000 (approximately $23,900) to our subsidiary. The trial court ordered defendants to pay CAD 1 billion (approximately $796 million) of the compensatory damage award, CAD 200 million (approximately $159 million) of which is our subsidiary’s portion, into a trust within 60 days.
  
In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.)
30

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
May 27, 2015    Canada/Cecilia Létourneau
   Class Action   
On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Létourneau class on liability and awarded a total of CAD 131 million (approximately $104 million) in punitive damages, allocating CAD 46 million (approximately $37 million) to RBH. The trial court ordered defendants to pay the full punitive damage award into a trust within 60 days. The court did not order the payment of compensatory damages.
  
In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.)
Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
August 5, 2016 Argentina/Hugo Lespada Individual Action
On August 5, 2016, the Civil Court No. 14 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded him ARS 110,000 (approximately $1,141), plus interest, in compensatory and moral damages. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes.
On August 23, 2016, our subsidiary filed its notice of appeal. On October 31, 2017, the Civil and Commercial Court of Appeals of Mar del Plata ruled that plaintiff's claim was barred by the statute of limitations and it reversed the trial court's decision. On November 28, 2017, plaintiff filed an extraordinary appeal of the reversal of the trial court's decision to the Supreme Court of the Province of Buenos Aires. On April 19, 2021, the Supreme Court of the Province of Buenos Aires rejected plaintiff's extraordinary appeal. On May 17, 2021 plaintiff filed a federal extraordinary appeal to the Federal Supreme Court. On June 16, 2021 our subsidiary filed its reply to the federal extraordinary appeal.
31

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
June 17, 2021 Argentina/Claudia Milano Individual Action
On June 17, 2021, the Civil Court No. 9 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded her smoking cessation treatments, ARS 150,000 (approximately $1,556), in compensatory and moral damages, and ARS 4,000,000 (approximately $41,500) in punitive damages, plus interest and costs. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes.
On July 2, 2021, our subsidiary filed its notice of appeal. In addition, plaintiff filed an appeal challenging the dismissal of the claim for psychological damages. As required by local law, our subsidiary will have to deposit the damages awarded, plus interest and costs, in total ARS 6,114,428 (approximately $63,438), into a court escrow account. Our subsidiary plans to challenge the amount determined by the court. If our subsidiary ultimately prevails on appeal, the deposited amounts will be returned to our subsidiary.
Pending claims related to tobacco products generally fall within the following categories:
Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause, assumption of the risk, contributory negligence, and statute of limitations.
As of July 23, 2021, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows:

44 cases brought by individual plaintiffs in Argentina (31), Brazil (3), Canada (2), Chile (2), China (1), Italy (1), the Philippines (1), Turkey (1) and Scotland (1), as well as 1 case brought by an individual plaintiff in the United States District Court for the District of Oregon in May 2021. The provisions of the 2008 Share Distribution Agreement between PMI and Altria provide for indemnities to PMI for certain liabilities concerning tobacco products as described above under the caption "Tobacco-Related Litigation," compared with 44 such cases on July 24, 2020, and 52 cases on July 23, 2019; and
9 cases brought on behalf of classes of individual plaintiffs in Canada, compared with 10 such cases on July 24, 2020 and 10 such cases on July 23, 2019.

The class actions pending in Canada are described above under the caption “Smoking and Health Litigation — Canada.

Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under statutes governing
32

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim, adequate remedy at law, “unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of cigarettes), and statute of limitations.
As of July 23, 2021, there were 17 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Brazil (1), Canada (10), Korea (1) and Nigeria (5), compared with 17 such cases on July 24, 2020 and 17 such cases on July 23, 2019.

The health care cost recovery actions pending in Canada are described above under the caption “Health Care Cost Recovery Litigation — Canada.
In the health care cost recovery case in Brazil, The Attorney General of Brazil v. Souza Cruz Ltda., et al., Federal Trial Court, Porto Alegre, Rio Grande do Sul, Brazil, filed May 21, 2019, we, our subsidiaries, and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases in certain prior years, payment of anticipated costs of treating future alleged smoking-related diseases, and moral damages. Defendants filed answers to the complaint in May 2020.
In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of challenging the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served.
In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al., High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants. Plaintiffs seek reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served.
In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court of Ogun State, Abeokuta, Nigeria, filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our objections to the court's jurisdiction. We have appealed. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.

In the health care cost recovery case in Korea, the National Health Insurance Service v. KT&G, et. al., filed April 14, 2014, our subsidiary and other Korean manufacturers are defendants. Plaintiff alleges that defendants concealed the health hazards of smoking, marketed to youth, added ingredients to make their products more harmful and addictive, and misled consumers into believing that Lights cigarettes are safer than regular cigarettes. The National Health Insurance Service seeks to recover
33

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
damages allegedly incurred in treating 3,484 patients with small cell lung cancer, squamous cell lung cancer, and squamous cell laryngeal cancer from 2003 to 2012. The trial court dismissed the case in its entirety on November 20, 2020. Plaintiff appealed.

Label-Related Cases: These cases, now brought only by individual plaintiffs, allege that the use of the descriptor “Lights” or other alleged misrepresentations or omissions of labeling information constitute fraudulent and misleading conduct. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including misrepresentation, deception, and breach of consumer protection laws. Plaintiffs seek various forms of relief including restitution, injunctive relief, and compensatory and other damages. Defenses raised include lack of causation, lack of reliance, assumption of the risk, and statute of limitations.

As of July 23, 2021, there were 4 label-related cases brought by individual plaintiffs in Italy (1) and Chile (3) pending against our subsidiaries, compared with 5 such cases on July 24, 2020, and 6 such cases on July 23, 2019.

Public Civil Actions: Claims have been filed either by an individual, or a public or private entity, seeking to protect collective or individual rights, such as the right to health, the right to information or the right to safety. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including product defect, concealment, and misrepresentation. Plaintiffs in these cases seek various forms of relief including injunctive relief such as banning cigarettes, descriptors, smoking in certain places and advertising, as well as implementing communication campaigns and reimbursement of medical expenses incurred by public or private institutions.

As of July 23, 2021, there were 2 public civil actions pending against our subsidiaries in Argentina (1) and Venezuela (1), compared with 2 such cases on July 24, 2020, and 2 such cases on July 23, 2019.

In the public civil action in Argentina, Asociación Argentina de Derecho de Danos v. Massalin Particulares S.A., et al., Civil Court of Buenos Aires, Argentina, filed February 26, 2007, our subsidiary and another member of the industry are defendants. The plaintiff, a consumer association, seeks the establishment of a relief fund for reimbursement of medical costs associated with diseases allegedly caused by smoking. Our subsidiary filed its answer in September 2007. In March 2010, the case file was transferred to the Federal Court on Administrative Matters after the Civil Court granted plaintiff's request to add the national government as a co-plaintiff in the case. The trial court dismissed the case on May 14, 2021.

In the public civil action in Venezuela, Federation of Consumers and Users Associations (“FEVACU”), et al. v. National Assembly of Venezuela and the Venezuelan Ministry of Health, Constitutional Chamber of the Venezuelan Supreme Court, filed April 29, 2008, we were not named as a defendant, but the plaintiffs published a notice pursuant to court order, notifying all interested parties to appear in the case. In January 2009, our subsidiary appeared in the case in response to this notice. The plaintiffs purport to represent the right to health of the citizens of Venezuela and claim that the government failed to protect adequately its citizens' right to health. The claim asks the court to order the government to enact stricter regulations on the manufacture and sale of tobacco products. In addition, the plaintiffs ask the court to order companies involved in the tobacco industry to allocate a percentage of their “sales or benefits” to establish a fund to pay for the health care costs of treating smoking-related diseases. In October 2008, the court ruled that plaintiffs have standing to file the claim and that the claim meets the threshold admissibility requirements. In December 2012, the court admitted our subsidiary and BAT's subsidiary as interested third parties. In February 2013, our subsidiary answered the complaint.

Reduced-Risk Products

In Colombia, an individual filed a purported class action, Ana Ferrero Rebolledo v. Philip Morris Colombia S.A., et al., in April 2019, against our subsidiaries with the Civil Court of Bogota related to the marketing of our Platform 1 product. Plaintiff alleged that our subsidiaries advertise the product in contravention of law and in a manner that misleads consumers by portraying the product in a positive light, and further asserts that the Platform 1 vapor contains many toxic compounds, creates a high level of dependence, and has damaging second-hand effects. Plaintiff sought injunctive relief and damages on her behalf and on a behalf of two classes (class 1 - all Platform 1 consumers in Colombia who seek damages for the purchase price of the product and personal injuries related to the alleged addiction, and class 2 - all residents of the neighborhood where the advertising allegedly took place who seek damages for exposure to the alleged illegal advertising). Our subsidiaries answered the complaint in January 2020, and in February 2020, plaintiff filed an amended complaint. The amended complaint modifies the relief sought on behalf of the named plaintiff and on behalf of a single class (all consumers of Platform 1 products in Colombia who seek damages for the product purchase price and personal injuries related to the use of an allegedly harmful product.) In June 2021, our subsidiaries answered the amended complaint.
34

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Other Litigation

The Department of Special Investigations of the government of Thailand ("DSI") conducted an investigation into alleged underpayment by our subsidiary, Philip Morris (Thailand) Limited ("PM Thailand"), of customs duties and excise taxes relating to imports from the Philippines covering the period 2003-2007. On January 18, 2016, the Public Prosecutor filed charges against our subsidiary and seven former and current employees in the Bangkok Criminal Court alleging that PM Thailand and the individual defendants jointly and with the intention to defraud the Thai government, under-declared import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries of cigarettes from the Philippines during the period of July 2003 to June 2006. The government is seeking a fine of approximately THB 80.8 billion (approximately $2.5 billion). In May 2017, Thailand enacted a new customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and other Thai governmental agencies. Trial in the case began in November 2017, and concluded in September 2019. In November 2019, the trial court found our subsidiary guilty of under-declaration of the prices and imposed a fine of approximately THB 1.2 billion (approximately $36 million). The trial court dismissed all charges against the individual defendants. In December 2019, as required by the Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal of charges against the individual defendants and the amount of the fine imposed. If our subsidiary ultimately prevails on appeal, then Thailand will be required to return this payment to our subsidiary.

The DSI also conducted an investigation into alleged underpayment by PM Thailand of customs duties and excise taxes relating to imports from Indonesia covering the period 2000-2003. On January 26, 2017, the Public Prosecutor filed charges against PM Thailand and its former Thai employee in the Bangkok Criminal Court alleging that PM Thailand and its former employee jointly and with the intention to defraud the Thai government under-declared import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries during the period from January 2002 to July 2003. The government is seeking a fine of approximately THB 19.8 billion (approximately $602 million). In May 2017, Thailand enacted a new customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and a Thai court. Trial in the case began in November 2018 and concluded in December 2019. In March 2020, the trial court found our subsidiary guilty of under-declaration of the prices and imposed a fine of approximately THB 130 million (approximately $4 million). The trial court dismissed all charges against the individual defendant. In April 2020, as required by Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal of charges against the individual defendant and the amount of the fine imposed. If our subsidiary ultimately prevails on appeal, then Thailand will be required to return this payment to our subsidiary.

The South Korean Board of Audit and Inspection (“BAI”) conducted an audit of certain Korean government agencies and the tobacco industry into whether inventory movements ahead of the January 1, 2015 increase of cigarette-related taxes by tobacco companies, including Philip Morris Korea Inc. ("PM Korea"), our South Korean subsidiary, were in compliance with South Korean tax laws.  In November 2016, the tax authorities completed their audit and assessed allegedly underpaid taxes and penalties.  In order to avoid nonpayment financial costs, PM Korea paid approximately KRW 272 billion (approximately $236 million), of which KRW 100 billion (approximately $87 million) was paid in 2016 and KRW 172 billion (approximately $149 million) was paid in the first quarter of 2017.  These paid amounts are included in other assets in the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment.  PM Korea appealed the assessments. In January 2020, a trial court ruled that PM Korea did not underpay taxes in the amount of approximately KRW 218 billion (approximately $189 million). The tax authorities appealed this decision to the appellate court. In September 2020, the appellate court upheld the trial court's decision. The tax authorities have appealed to the Supreme Court of South Korea. In June 2020, another trial court ruled that PM Korea did not underpay approximately KRW 54 billion (approximately $46 million) of alleged underpayments. The government agencies appealed this decision. In January 2021, the appellate court upheld the trial court's decision. The government agencies appealed
35

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
to the Supreme Court of South Korea. If the tax authorities and government agencies ultimately lose, then they would be required to return the paid amounts to PM Korea.

The Moscow Tax Inspectorate for Major Taxpayers (“MTI”) conducted an audit of AO Philip Morris Izhora (“PM Izhora”), our Russian subsidiary, for the 2015-2017 financial years. On July 26, 2019, MTI issued its initial assessment, claiming that intercompany sales of cigarettes between PM Izhora and another Russian subsidiary prior to excise tax increases and submission by PM Izhora of the maximum retail sales price notifications for cigarettes to the tax authorities were improper under Russian tax laws and resulted in underpayment of excise taxes and VAT. In August 2019, PM Izhora submitted its objections disagreeing with MTI’s allegations set forth in the initial assessment and MTI’s methodology for calculating the alleged underpayments. MTI accepted some of PM Izhora’s arguments, and in September 2019, issued the final tax assessment claiming an underpayment of RUB 24.3 billion (approximately $374 million), including penalties and interest. In accordance with Russian tax laws, PM Izhora paid the entire amount of MTI’s final assessment. This amount was neither imposed on, nor concurrent with, the specific revenue-producing transaction, nor was it collected from customers of our Russian subsidiaries. In the third quarter of 2019, PMI recorded a pre-tax charge of $374 million, in marketing, administration and research costs in the condensed consolidated statements of earnings, representing $315 million net of an associated income tax benefit of $59 million.

The Saudi Arabia Customs General Authority issued its assessments requiring our distributors to pay additional customs duties in the amount of approximately 1.5 billion Saudi Riyal, or approximately $396 million, in relation to the fees paid by these distributors under their agreements with our subsidiary for exclusive rights to distribute our products in Saudi Arabia. In order to challenge these assessments, the distributors posted bank guarantees. To enable the distributors' challenge, our subsidiary agreed with the banks to bear a portion of the amount the authority may draw on the bank guarantees. In September and October 2020, respectively, the distributors lost their challenges of the assessments. Both distributors appealed, and in June 2021, the Customs Appeal Committee in Riyadh notified the distributors of its decisions to largely reject their appeals. On the basis of the above-mentioned decisions, in June 2021, PMI recorded a pre-tax charge of $246 million in relation to the period of 2014 through 2020 in line with existing and contemplated arrangements with the distributors. The estimated amounts for 2021 are immaterial. In accordance with U.S. GAAP, the charge was recorded as a reduction in net revenues on the consolidated statements of earnings for the three months and six months ended June 30, 2021. Despite the unfavorable decisions, our subsidiary believes that customs duties paid in Saudi Arabia were in compliance with the applicable law and the WTO Customs Valuation Agreement.

A putative shareholder class action lawsuit, In re Philip Morris International Inc. Securities Litigation, is pending in the United States District Court for the Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between July 26, 2016 and April 18, 2018.  The lawsuit names Philip Morris International Inc. and certain officers and employees as defendants and includes allegations that the defendants made false and/or misleading statements and/or failed to disclose information about PMI’s business, operations, financial condition, and prospects, related to product sales of, and alleged irregularities in clinical studies of, PMI’s Platform 1 product.  The lawsuit seeks various forms of relief, including damages. In November 2018, the court consolidated three putative shareholder class action lawsuits with similar allegations previously filed in the Southern District of New York (namely, City of Westland Police and Fire Retirement System v. Philip Morris International Inc., et al, Greater Pennsylvania Carpenters’ Pension Fund v. Philip Morris International Inc., et al., and Gilchrist v. Philip Morris International Inc., et al.) into these proceedings. A putative shareholder class action lawsuit, Rubenstahl v. Philip Morris International Inc., et al., that had been previously filed in December 2017 in the United States District Court for the District of New Jersey, was voluntarily dismissed by the plaintiff due to similar allegations in these proceedings. On February 4, 2020, the court granted defendants’ motion in its entirety, dismissing all but one of the plaintiffs’ claims with prejudice.  The court noted that one of plaintiffs’ claims (allegations relating to four non-clinical studies of PMI’s Platform 1 product) did not state a viable claim but allowed plaintiffs to replead that claim by March 3, 2020. On February 18, 2020, the plaintiffs filed a motion for reconsideration of the court's February 4th decision; this motion was denied on September 21, 2020. On September 28, 2020, plaintiffs filed an amended complaint seeking to replead allegations relating to four non-clinical studies of PMI's Platform 1 product. We believe that this lawsuit is without merit and will continue to defend it vigorously.

In April 2020, affiliates of British American Tobacco plc (“BAT”) commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Altria Client Services LLC, et al.,  in the federal court in the Eastern District of Virginia, where PMI's subsidiary, Philip Morris Products S.A., as well as Altria Group, Inc.'s subsidiaries, are defendants. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 products in the United States.  In April 2020, BAT affiliates filed a complaint against PMI, Philip Morris Products S.A., Altria Group, Inc., and its subsidiaries before the International Trade Commission ("ITC"). Plaintiffs seek an order to prevent the importation of Platform 1 products into the United States.
36

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The ITC evidentiary hearing closed on February 1, 2021. On May 14, 2021, the administrative law judge issued an Initial and Recommended Determination ("ID/RD") finding that the Platform 1 product infringes two of the three patents asserted by Plaintiffs, recommending that the ITC issue a Limited Exclusion order against infringing products, and recommending against a cease-and-desist, as well as recommending against a bond pending Presidential review of the ITC's Final Determination. Defendants and Plaintiffs filed separate Petitions for Review with the ITC of the ID on May 28, 2021; a decision on those petitions is expected on July 27, 2021. Plaintiffs and Defendants also submitted brief statements of the public interest factors in issue to the ITC on June 15, 2021. The ITC's Final Determination is expected in mid-September 2021. In June 2020, defendants filed their responses in both proceedings. In the Eastern District of Virginia case, the defendants also counterclaimed that BAT infringed their patents relating to certain e-vapor products, seeking damages for, and injunctive relief against, the commercialization of these products by BAT; defendants' claims against BAT are set for trial on April 4, 2022. Upon petition of Philip Morris Products S.A., the Patent Trial and Appeal Board of the United States Patent and Trademark Office has instituted review of certain claims pertaining to four of the six patents asserted by BAT affiliates in both proceedings.

In April 2020, BAT’s affiliate commenced patent infringement proceedings, Nicoventures Trading Limited v. PM GmbH, et al., against PMI’s German subsidiary, Philip Morris GmbH, and Philip Morris Products S.A., in the Regional Court in Munich, Germany. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 products in Germany.

In July 2020, in response to a challenge in the United Kingdom by PMI’s subsidiary to patents related to the BAT patents in the German proceedings, BAT affiliates brought a patent infringement action, Nicoventures Trading Limited, et al. v. Philip Morris Products S.A., et al., against Philip Morris Products S.A. and PMI’s U.K. subsidiary, Philip Morris Limited, in the English High Court, seeking damages and injunctive relief against the commercialization of the Platform 1 products in the United Kingdom. On March 9, 2021, the court revoked the BAT patents and found that, had the BAT patents not been revoked as invalid, they would have been infringed. BAT affiliates sought to appeal the court’s judgment and the U.K. Court of Appeal refused BAT's request to appeal.

In September 2020, BAT’s affiliates commenced patent infringement and unfair competition proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Products S.A., et al., against Philip Morris Products S.A. and PMI’s Italian subsidiaries, Philip Morris Manufacturing & Technology Bologna S.p.A. and Philip Morris Italia S.r.l., in the Court of Milan, Italy. Plaintiffs seek damages, as well as injunctive relief against the manufacture in Italy of the Platform 1 heated tobacco units allegedly infringing the asserted patents and the commercialization of the Platform 1 products in Italy. As part of this proceeding, in October 2020, BAT’s affiliates filed a request based on one of the two asserted patents seeking preliminary injunctive relief against the manufacture and commercialization of the Platform 1 products in Italy.

In October 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Japan, Limited, et al., against PMI’s Japanese subsidiary, Philip Morris Japan Limited, and a third-party distributor in the Tokyo District Court. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 products in Japan.

In November 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Romania SRL, et al., against PMI’s Romanian subsidiaries, Philip Morris Romania S.R.L. and Philip Morris Trading S.R.L., and a third-party distributor in the Court of Law of Bucharest, Civil Registry. Plaintiffs seek damages and preliminary and permanent injunctive relief against the manufacture and commercialization of the Platform 1 products in Romania. In February 2021, the court dismissed plaintiffs’ request for a preliminary injunction. In April 2021, the appellate court denied plaintiffs' appeal, confirming the dismissal of plaintiffs' request for preliminary injunction. Plaintiffs' proceeding requesting damages and a permanent injunction remains pending before the Court of Law of Bucharest, Civil Registry.

In February 2021, BAT’s affiliate commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Papastratos SA, et al., against PMI’s Greek subsidiary, Papastratos Cigarettes Manufacturing Company S.A., and Philip Morris Products S.A., in the First Instance Court of Athens. Plaintiff seeks preliminary injunctive relief against the commercialization of the Platform 1 products in Greece. In July 2021, the court dismissed plaintiffs' request in its entirety.

In March 2021, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Korea, Co., Ltd., against PM Korea in the Seoul Central District Court. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 heated tobacco units in South Korea.

Other patent challenges by both parties are pending in various jurisdictions.

We believe that the foregoing proceedings by the affiliates of BAT are without merit and will defend them vigorously.
37

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

We are also involved in additional litigation arising in the ordinary course of our business. While the outcomes of these proceedings are uncertain, management does not expect that the ultimate outcomes of other litigation, including any reasonably possible losses in excess of current accruals, will have a material adverse effect on our consolidated results of operations, cash flows or financial position.

Third-Party Guarantees

On October 17, 2020, Medicago Inc., an equity method investee of Philip Morris Investments B.V. (“PMIBV”), a PMI subsidiary, entered into a contribution agreement with the Canadian government (the “Contribution Agreement”), whereby the Canadian government agreed to contribute up to CAD 173 million (approximately $131 million on the date of signing) to Medicago Inc., to support its on-going COVID-19 vaccine development and clinical trials, and for the construction of its Quebec City manufacturing facility (the “Project”). PMIBV and the majority shareholder of Medicago Inc. are also parties to the Contribution Agreement as guarantors of Medicago Inc.’s obligations thereunder on a joint and several basis (“Co-Guarantors”). The Co-Guarantors agreed to repay amounts contributed by the Canadian government plus interest, if Medicago Inc. fails to do so, and could be responsible for the costs of other Medicago’s obligations (such as the achievement of specific milestones of the Project). The maximum amount of these obligations is currently non-estimable. As of June 30, 2021, PMI has determined that these guarantees did not have a material impact on its condensed consolidated financial statements.

In connection with the Contribution Agreement, PMIBV and the majority shareholder of Medicago Inc. entered into a guarantors’ agreement that apportions Co-Guarantors’ obligations and limits those of PMIBV to its then share of holdings in Medicago Inc., which as of June 30, 2021 was approximately 32%. In July 2021, Medicago Inc. initiated an additional round of equity funding in which PMIBV did not participate. As a result, PMIBV’s share of holdings in Medicago Inc. was reduced to approximately 25%. The guarantees are in effect through March 31, 2026.

Note 9. Income Taxes:
Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets.

On March 11, 2021, the American Rescue Plan Act of 2021 ("the Act") was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. As of June 30, 2021, PMI has determined that the Act had no significant impact on PMI's effective tax rate.

PMI’s effective tax rates for the six months and three months ended June 30, 2021 were 21.7% and 22.0%, respectively. PMI’s effective tax rates for the six months and three months ended June 30, 2020 were 21.7% and 20.7%, respectively. The effective tax rate for the six months ended June 30, 2021 was favorably impacted by the corporate income tax rate reduction in the Philippines (enacted in the first quarter of 2021). The effective tax rate for the six months ended June 30, 2020 was favorably impacted by the corporate income tax rate reduction in Indonesia (enacted in the second quarter of 2020). PMI estimates that its full-year 2021 effective tax rate will be around 22%, excluding discrete tax events. Changes in currency exchange rates, earnings mix by taxing jurisdiction or future regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant judgment is required in determining income tax provisions and in evaluating tax positions.

PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of limitations remains open for the years 2017 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from three to five years.

It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits along with related interest and penalties. An estimate of any possible change cannot be made at this time.

38

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 10. Indebtedness:
Short-term Borrowings:
PMI's short-term borrowings, consisting of bank loans to certain PMI subsidiaries at June 30, 2021 and December 31, 2020, had a carrying value of $136 million and $244 million, respectively. The fair values of PMI’s short-term borrowings, based on current market interest rates, approximate carrying value.

Long-term Debt:
At June 30, 2021 and December 31, 2020, PMI’s long-term debt consisted of the following:

(in millions) June 30, 2021 December 31, 2020
U.S. dollar notes, 0.875% to 6.375% (average interest rate 3.232%), due through 2044
$ 20,134  $ 21,221 
Foreign currency obligations:
Euro notes, 0.125% to 3.125% (average interest rate 1.995%), due through 2039
8,082  9,253 
Swiss franc notes, 1.625% to 2.000% (average interest rate 1.830%), due through 2024
597  622 
Other (average interest rate 3.724%), due through 2025 (a)
209  196 
Carrying value of long-term debt 29,022  31,292 
Less current portion of long-term debt 1,608  3,124 
  $ 27,414  $ 28,168 
(a) Includes mortgage debt in Switzerland as well as $56 million and $37 million in finance leases at June 30, 2021 and December 31, 2020, respectively.


The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates currently available to PMI for issuances of debt with similar terms and remaining maturities. At June 30, 2021, the fair value of PMI's outstanding long-term debt, excluding the aforementioned finance leases, was as follows:

(in millions)
June 30, 2021
Level 1 $ 31,789 
Level 2 167 
For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2020.

Credit Facilities:

On January 29, 2021, PMI entered into an agreement to amend and extend the term of its 364-day revolving credit facility from February 2, 2021, to February 1, 2022 in the amount of $1.75 billion.

39

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
At June 30, 2021, PMI's total committed credit facilities were as follows:

(in billions)


Type
Committed
Credit
Facilities
364-day revolving credit, expiring February 1, 2022
$ 1.75 
Multi-year revolving credit, expiring October 1, 2022
3.50 
Multi-year revolving credit, expiring February 10, 2025(a)
2.00 
Total facilities
$ 7.25 
(a) On January 29, 2021, PMI entered into an agreement, effective February 10, 2021, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2025 to February 10, 2026, in the amount of $1.86 billion. Effective July 2, 2021, the total facility amount for this additional year is $1.95 billion.

At June 30, 2021, there were no borrowings under these committed credit facilities, and the entire committed amounts were available for borrowing.

Note 11. Accumulated Other Comprehensive Losses:
PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
(Losses) Earnings At At At
(in millions) June 30, 2021 December 31, 2020